Lil­ly's Covid-19 mAb no longer au­tho­rized due to Omi­cron sub­vari­ants, FDA says

The FDA on Wednes­day an­nounced that Eli Lil­ly’s Covid-19 drug bebtelovimab is no longer au­tho­rized to treat Covid-19 be­cause of the ris­ing num­bers of two new sub­vari­ants that the drug does not work against.

The Cen­ters for Dis­ease Con­trol and Pre­ven­tion last week pub­lished new es­ti­mates that the com­bined pro­por­tion of Covid-19 cas­es caused by the Omi­cron sub­vari­ants BQ.1 and BQ.1.1 are greater than 57% na­tion­al­ly, and al­ready above 50% in all in­di­vid­ual re­gions but one.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.